Mereo BioPharma Group plc Mereo BioPharma Appoints Wills Hughes-Wilson (8347F)
26 February 2018 - 6:00PM
UK Regulatory
TIDMMPH
RNS Number : 8347F
Mereo BioPharma Group plc
26 February 2018
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Mereo BioPharma Appoints Wills Hughes-Wilson as Head of Patient
Access and Commercial Planning
London, 26 February 2018 - Mereo BioPharma Group plc (AIM: MPH),
a multi-asset biopharmaceutical company focused on the acquisition,
development and commercialization of innovative therapeutics that
aim to improve outcomes for patients with rare and specialty
diseases, today announced the appointment of Wills Hughes-Wilson as
Head of Patient Access and Commercial Planning. In her role, Ms.
Hughes-Wilson will be responsible for leading and optimizing
Mereo's patient access and commercialization strategies, initially
in a part-time role as the Company builds out its rare disease
commercial infrastructure.
Dr. Denise Scots-Knight, Chief Executive Officer of Mereo
BioPharma commented "Ms. Hughes-Wilson brings in-depth market
access and product launch expertise as well as a proven ability to
develop and lead commercial planning efforts globally. With
extensive experience in the rare and orphan disease areas, Ms.
Hughes-Wilson will be instrumental as we advance our portfolio of
rare product candidates through late-stage clinical development and
towards commercialization. We are very pleased to welcome her and
believe she will be a strong complement to our existing leadership
team at Mereo."
Most recently, Ms. Hughes-Wilson served on the Executive
Leadership Team as Chief Patient Access Officer and Senior Vice
President Access & External Affairs at Swedish Orphan Biovitrum
(Sobi), an international specialty healthcare company dedicated to
rare diseases. In her role, Ms. Hughes-Wilson was responsible for
Sobi's go-to-market commercialization approach and led the pricing,
reimbursement and access teams for Sobi's rare disease product
portfolio. Prior to joining Sobi, Ms. Hughes-Wilson served as Vice
President of Health and Market Access Policy at Genzyme Corporation
(now part of Sanofi).
"I am thrilled to join Mereo's leadership team at such a pivotal
time for the Company," Ms. Hughes-Wilson stated. "Mereo's robust
portfolio of product candidates, including BPS-804 for the
treatment of osteogenesis imperfecta and AZD-9668 for the treatment
of severe alpha-1 antitrypsin deficiency, has the potential to
address significant unmet medical needs in rare diseases. I look
forward to applying my experience to help the Company continue its
journey to develop these therapies and, if approved, make them
commercially available to patients and healthcare systems in a
timely and sustainable manner."
About Mereo
Mereo is a multi-asset biopharmaceutical company focused on the
acquisition, development and commercialization of innovative
therapeutics that aim to improve outcomes for patients with rare
and specialty diseases. The portfolio consists of four
clinical-stage product candidates, each of which were acquired from
large pharmaceutical companies: BPS-804 for the treatment of
osteogenesis imperfecta; AZD-9668 for the treatment of severe
alpha-1 antitrypsin deficiency; BCT-197 for the treatment of acute
exacerbations of chronic obstructive pulmonary disease, or AECOPD;
and BGS-649 for the treatment of hypogonadotropic hypogonadism in
obese men. Each of the Company's product candidates has generated
positive clinical data for Mereo's target indication or in a
related indication. The Company's strategy is to selectively
acquire product candidates that have already received significant
investment from pharmaceutical companies and that have substantial
preclinical, clinical and manufacturing data packages. Since
inception the Company has commenced large, randomized,
placebo-controlled Phase 2 clinical trials for three of the product
candidates and announced positive top-line results from its Phase 2
clinical trial of BCT-197 as an acute therapy for patients with
AECOPD in December 2017. The Company intends to commence additional
late-stage clinical trials in 2018.
For Further Enquiries:
+44 (0)333 023
Mereo BioPharma Group plc 7318
Denise Scots-Knight, Chief Executive
Officer
Richard Jones, Chief Financial Officer
Nominated Adviser and Joint Broker +44(0)20 7894
Cantor Fitzgerald Europe 7000
Phil Davies
Will Goode
Joint Broker +44 (0)20 7653
RBC Capital Markets 4000
Rupert Walford
Laura White
EU Public Relations Adviser to Mereo +44 (0)20 3727
FTI Consulting 1000
Ben Atwell
Simon Conway
Brett Pollard
US Public Relations Advisor to Mereo +01 (0) 212
Burns McClellan 213 0006
Lisa Burns
Steven Klass
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSEAFIDFASEDE
(END) Dow Jones Newswires
February 26, 2018 02:00 ET (07:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024